Cabazitaxel in Relapsed and Metastatic NSCLC

NCT01852578 | Completed Phase 2

• 1 other identifier: CT/12.02
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 5

Brief Summary

The investigators propose to study the single agent activity of Cabazitaxel in a Phase II trial of subjects with relapsed or refractory non-small cell lung cancer pretreated with docetaxel, given the fact of its significant activity and its acceptable toxicity profile.

Conditions

NSCLC

Keywords

Metastatic NSCLC; 2nd Line; Docetaxel-based treatment; Progressed; Refractory

Outcome Measures

Primary Outcomes (1)

• Overall Response Rate

  Disease evaluation at Week 6

Secondary Outcomes (4)

• Disease control rate

  Disease evaluation at Week 6

• Progression Free Survival

  1 year

• Overall Survival

  1 year

• Toxicity profile

  Every 3 weeks

Study Arms (1)

1

EXPERIMENTAL

Drug: Cabazitaxel

Interventions

Cabazitaxel DRUG

Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks

Also known as: Jevtana

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age\>18 years old
• Cytologically or histologically documented NSCLC
• PS 0-2 (WHO scale)
• Measurable disease according to Response Evaluation Criteria in Solid Tumors (at least one measurable lesion)
• Documented disease progression to previous treatment with docetaxel regimen in 1st or 2nd line setting assessed by Response Evaluation Criteria in Solid Tumors with at least one visceral or soft-tissue metastatic lesion.
• Brain metastases are allowed, given that are clinically stable and the patient does not present neurologic symptoms.
• Previous radiotherapy, either in the adjuvant setting or for the treatment of bone metastases, is allowed provided that the measurable lesions are outside the radiation fields. Patients who were irradiated to ≥ 40% of bone marrow are not eligible for the study.
• Patients must have a recent (within 7 days prior to treatment start) biochemical and hematogical assessment as defined by adequate bone marrow (absolute neutrophil count ≥1.5 x 109 cells/L, platelets ≥100 x 109cells/L and hemoglobin ≥9 g/dL), liver (AST \& ALT ≤ 2.5x ULN, total bilirubin within normal range) and renal (serum creatinine \< 1.5 x ULN). If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance \<60 mL/min should be excluded) function tests
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
• Before patient enrollment, written informed consent must be given according to ICH/GCP and national/local regulations.

You may not qualify if:

• Persistence of clinically relevant treatment-related toxicities from previous chemotherapy or radiotherapy.
• Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of treatment or concomitantly with this trial.
• Other malignancy within the past five years other than basal cell skin cancer or carcinoma in situ of the cervix.
• Patient with reproductive potential not implementing accepted and effective method of contraception
• History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing drugs or to docetaxel
• Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus, hypertension, heart failure ≤ NYHA II, history of myocardial infarction within the past 6 months, angina, chronic obstructive pulmonary disease (COPD), serious infections requiring systemic antibiotic therapy (e.g. antimicrobial, antifungal, antiviral)
• Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix A and B)
• Prior surgery, radiation, chemotherapy, within 4 weeks prior to treatment
• Active grade ≥2 peripheral neuropathy
• Active grade ≥2 stomatitis

Sponsors & Collaborators

• Hellenic Oncology Research Group: lead

Study Sites (5)

"Ag. Georgios" General Hospital of Chania

Chania, Crete, Greece

Location

University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece

Heraklion, Crete, Greece

Location

"IASO" General Hospital of Athens Athens, Greece

Athens, Greece

Location

Air Forces Military Hospital of Athens Athens, Greece

Athens, Greece

Location

"PAPAGEORGIOY" General Hospital of Thessaloniki

Thessaloniki, Greece

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

cabazitaxel

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Athanasio Kotsakis, MD

  University Hospital of Herklion

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 9, 2013
• First Posted: May 13, 2013
• Study Start: September 1, 2012
• Primary Completion: August 1, 2013
• Study Completion: August 1, 2013
• Last Updated: September 28, 2015

Record last verified: 2015-09

Locations

GR (5)